Y-Intercept (HK)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Y-Intercept (HK)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.59M	Sell	10,113 -45,720	-82%	-$7.22M	0.04%	743
2026 Q2	$8.84M	Buy	55,833 +49,087	+728%	+$6.64M	0.17%	117
2026 Q1	$862K	Buy	+6,746	New	+$842K	0.02%	1090
2025 Q4	–	Sell	-18,828	Closed	-$1.89M	–	2039
2025 Q3	$1.89M	Buy	18,828 +12,242	+186%	+$1.1M	0.05%	640
2025 Q2	$546K	Buy	+6,586	New	+$525K	0.01%	1176
2024 Q3	–	Sell	-9,083	Closed	-$842K	–	1872
2024 Q2	$842K	Buy	9,083 +392	+5%	+$35.1K	0.05%	571
2024 Q1	$825K	Buy	+8,691	New	+$806K	0.06%	466
2023 Q1	–	Sell	-3,222	Closed	-$267K	–	1592
2022 Q4	$267K	Sell	3,222 -1,283	-28%	-$104K	0.04%	713
2022 Q3	$357K	Buy	+4,505	New	+$380K	0.04%	644
2021 Q2	–	Sell	-7,351	Closed	-$956K	–	948
2021 Q1	$956K	Buy	+7,351	New	+$1.1M	0.26%	105

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.72% 1-Year Est. Return

Moss Adams Wealth Advisors Seattle, Washington $1.53B AUM 19.03% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.42B AUM 33.31% 1-Year Est. Return

J. Safra Asset Management New York $2.3B AUM 21.55% 1-Year Est. Return

Y-Intercept (HK)'s XBI Position: Q3 2026 in Review

Y-Intercept (HK) reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 82% in Q3 2026, selling an estimated $7.22M and leaving 10,113 shares worth $1.59M. The position accounts for 0.04% of the portfolio, ranked #743.

Y-Intercept (HK) first reported a position in XBI in Q1 2021 and has held it in 10 quarters since. The position peaked at $8.84M in Q2 2026. 450 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Y-Intercept (HK) held 10,113 shares of State Street SPDR S&P Biotech ETF worth $1.59M as of Q3 2026.
Y-Intercept (HK) sold 45,720 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $7.22M.
State Street SPDR S&P Biotech ETF made up 0.04% of Y-Intercept (HK)'s portfolio in Q3 2026, its #743 holding.
Y-Intercept (HK) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2021 and has held it in 10 quarters since.
Y-Intercept (HK)'s State Street SPDR S&P Biotech ETF position peaked at $8.84M in Q2 2026.
450 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.